Biotech

Latest Articles

Basilea scores $268M BARDA backing for antifungals, anti-biotics

.Basilea Pharmaceutica's work developing brand new antifungals has gotten a significant boost from t...

Capricor offers Europe rights to late-stage DMD therapy for $35M

.Possessing actually scooped up the USA legal rights to Capricor Therapies' late-stage Duchenne musc...

FDA scraps adcomm for Applied's uncommon ailment medication

.After dismissing the decision meeting for Applied Rehabs' metabolic disorder medication govorestat,...

Novo inks $600M NanoVation package to research genetic medicines ex-liver

.Novo Nordisk is continuing its press into hereditary medications, accepting compensate NanoVation T...

Innovent hyperlinks cytokine to colorectal cancer cells feedbacks

.Innovent Biologics has actually made the case that its checkpoint inhibitor-cytokine fusion protein...

Merck, Daiichi ADC reaches target in phase 3 bronchi cancer study

.A phase 3 trial of Daiichi Sankyo and Merck &amp Co.'s HER3-directed antibody-drug conjugate (ADC) ...

Rakovina deepens AI center with collab to select cancer targets

.Five months after Rakovina Therapies pivoted towards artificial intelligence, the cancer-focused bi...

Ascendis' dwarfism medication hits in stage 3, intimidates BioMarin

.Ascendis Pharma has emerged as a potential threat to BioMarin's Voxzogo, stating phase 3 growth dis...

Despite ph. 3 miss, Alkeus finds pathway in advance for eye disease property

.Though Alkeus Pharmaceuticals' dental eye disease asset fell short to significantly lessen geograph...

Kairos goes social along with $6M IPO to money trials of cancer cells medicine

.With a triad of biotechs striking the Nasdaq on Friday, it was actually quick and easy to miss out ...

Vaccine as well as Keytruda combination reliable in squamous tissue cancer

.Invulnerable checkpoint inhibitors are the superheroes of cancer cells treatment. Medications like ...

Cue Biopharma mark time J&ampJ vet as CBO-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our roundup of considerable leadership hirings, firings ...

Regeneron's Opdualag opponent reveals 57% response price

.Regeneron is actually back along with lasting consequence for its own LAG-3 prevention and PD-1 inh...

AstraZeneca messages data on in-house opponents to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed an early examine the performance of its internal antibody-drug c...

iTeos- GSK's TIGIT star reveals relevant improvement

.After declaring a phase 3 launch based upon good midstage outcomes, iTeos and also GSK are actually...

More collaborative FDA may increase unusual ailment R&ampD: document

.The FDA should be actually much more available and joint to release a surge in approvals of rare ai...

Zenas, MBX, Bicara head to Nasdaq in hot time for biotech IPOs

.It is actually an uncommonly active Friday for biotech IPOs, along with Zenas BioPharma, MBX and al...

Atea's COVID antiviral stops working to stop hospitalizations in phase 3

.Atea Pharmaceuticals' antiviral has actually fallen short another COVID-19 test, however the biotec...

Neurocrine's offer to conserve mental illness possibility falls short

.Neurocrine Biosciences' mental illness plan pivot has actually stopped working. The biotech was inc...

Sanofi pays for $110M upfront for late-stage radioligand treatment

.Sanofi has made an overdue access to the radioligand gathering, paying out 100 million europeans ($...